Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).

Cell Death Dis · 2022 · PMC9279493 · PMID 35831283

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

And consistent with our scRNA findings, IgG1, and IgG3 positive cells showed an increasing trend in MPR tumor lesions (mean IgG1: 2.13% versus 1.41% versus 2.92%; mean IgG3: 0.32% versus 0.25% versus 0.52%), while IgA positive cells showed a decreasing trend in MPR tumor lesions (mean 1.62% versus 1.51% versus 0.72%; Fig. 2D, F ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.